New Alzheimer’s drug may not be available for a few more months

Fox News writes “The first drug proven to slow Alzheimer’s is on sale, but most U.S. patients will not be able to receive the treatment for several months.

Experts say some reasons behind the slow debut for Leqembi, from Japanese drugmaker Eisai, are minimal insurance coverage and many health systems requiring a setup that takes a long time.

The drug, which was approved by the Food and Drug Administration in January, delivers an uncertain benefit. It is designed for patients with mild or early cases of dementia tied to Alzheimer’s disease.”

Read the full article here.

Related Articles